Natalizumab and Associated Biosimilar(s)
Customize your policy alerts
Sign up for healthspring Policy RX501.059 alerts
Get alerted when Policy RX501.059 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage for natalizumab (Tysabri) and natalizumab-sztn (Tyruko) for relapsing multiple sclerosis and moderately to severely active Crohn disease in adults. Other non-FDA-approved indications are considered experimental, investigational, and/or unproven, subject to applicable benefit terms and state requirements.
A new medical policy establishes coverage consideration for natalizumab and natalizumab-sztn for multiple sclerosis and Crohn disease when indication-specific criteria are met.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.